银屑病早期干预使用guselkumab提高稳定完全皮损清除率:GUIDE研究28周结果
GUIDE是一项IIIb期随机双盲平行组多中心研究,纳入880例中重度斑块状银屑病患者,按病程≤2年(SDD)或>2年(LDD)分组接受guselkumab 100 mg治疗。第28周时SDD组较LDD组更多达到PASI=0(51.8% vs 39.4%)和超级应答(43.7% vs 28.1%),SDD组达到PASI=0更快(中位141 vs 200天)。
要点
- SDD组第28周PASI=0比例51.8%,高于LDD组的39.4%。
- SDD组超级应答比例43.7%,高于LDD组的28.1%(总体34.4%)。
- SDD组达到PASI=0的中位时间141天,短于LDD组的200天。
核心结论
- Guselkumab在皮肤和系统性疗效在各亚组中一致。
- SDD患者超级应答比例高于LDD患者,提示早期治疗干预可能改善临床结局。
研究设计与样本
- IIIb期随机、双盲、平行组、多中心研究,纳入880例中重度斑块状银屑病成人患者。
- 患者按病程分为短病程(SDD,≤2年)和长病程(LDD,>2年),接受guselkumab 100 mg于第0、4、12、20周给药。
- 第20周和第28周均达到完全皮损清除者定义为超级应答者(SRe)。
主要发现
- SDD组第28周绝对PASI=0比例为51.8%,LDD组为39.4%。
- SDD组超级应答比例为43.7%,LDD组为28.1%,总体为34.4%。
- SDD组达到PASI=0的中位时间为141天,LDD组为200天。
- 病程和既往生物制剂使用对成为SRe影响最大,但这些独立变量之间无强关联。
- 基线时SDD与LDD之间、SRe与非SRe之间血清IL-17A、IL-17F、IL-22和β-防御素2水平无显著差异;第4周时guselkumab在所有分析组中快速降低这些系统性炎症标志物。
关键数值与推荐
- 超级应答者(SRe)定义为第20周和第28周均达到完全皮损清除。
- 短病程(SDD)定义为病程≤2年,长病程(LDD)定义为病程>2年。
临床怎么用
- Guselkumab 100 mg于第0、4、12、20周给药用于中重度斑块状银屑病。
- SDD患者接受guselkumab治疗第28周达到PASI=0和超级应答的比例高于LDD患者。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guselkumab is an interleukin (IL)-23 inhibitor with demonstrated efficacy in patients with psoriasis. OBJECTIVES: Evaluate the impact of early disease intervention on clinical responses following 28 weeks of guselkumab treatment in patients with moderate-to-severe plaque psoriasis. Correlate clinical response and disease duration data with serum biomarker data. METHODS: GUIDE is a phase IIIb randomized, double-blind, parallel-group, multicentre study of adults with moderate-to-severe plaque psoriasis. In study part 1, patients with a short disease duration (SDD [≤2 years]) or a long disease duration (LDD [>2 years]) received guselkumab 100 mg at Week (W) 0, 4, 12, and 20. Those achieving complete skin clearance at W20 and W28 were defined as a super responder (SRe). A multivariable logistic regression analysed the association between baseline factors and the likelihood of becoming an SRe. The relationship between clinical response, disease duration and serum biomarker data was assessed at W0 and 4. RESULTS: In total, 880 patients were enrolled (SDD/LDD = 40.6%/59.4% of patients). More SDD than LDD patients achieved absolute Psoriasis Area and Severity Index (PASI) = 0 at W28 (51.8% vs. 39.4%) and were SRes (43.7% vs. 28.1% [overall 34.4%]). SDD patients also achieved PASI = 0 quicker than LDD patients (median 141 vs. 200 days). Disease duration and prior biologic use had the greatest impact on becoming an SRe, with no strong association among these independent variables. At baseline, there were no significant differences in the serum biomarker levels of IL-17A, IL-17F, IL-22 and β-defensin 2 between SDD and LDD patients, or between SRe and non-SRe patients. Guselkumab rapidly decreased these markers of systemic inflammation across all patient groups analysed at W4. Guselkumab was well tolerated. CONCLUSIONS: Guselkumab efficacy was consistent across subpopulations, on the skin and systemically. The proportion of SRes was higher in SDD than LDD patients, indicating early treatment intervention may improve clinical outcomes.
引用
- Schäkel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023. PMID: 37262309. doi:10.1111/jdv.19236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。